12:36 PM EST, 12/06/2024 (MT Newswires) -- Rapport Therapeutics ( RAPP ) said Friday that data from a proof-of-concept study of RAP-219 showed a link between a seizure biomarker and clinical seizures.

The data showed that a 30% reduction in long episode frequency was associated with a decrease of at least 50% in clinical seizures, regardless of the antiseizure medication used, according to the company.

This sets the benchmark for evaluating the potential efficacy of antiseizure treatments, including RAP-219, the company said.

Price: 20.17, Change: -0.11, Percent Change: -0.52